Skip to content

Study · Observational study · n = 36 · 2022

7 results

LBODP006 Clinical Usefulness Of The Growth Hormone-releasing Peptide-2 Test For Hypothalamic-pituitary Disorder

The source lists no authors.

Journal of the Endocrine Society1 Nov 2022

PMCIDPMC9624549 (opens in a new tab)PepBankPUB-93334300
Read at sourceSource pageAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyOther

    Among 36 patients with hypothalamic-pituitary disorder, 61% had severe GH deficiency by the GHRP2 test.

    In plain wordsIn people with hypothalamic-pituitary disorder, 61% had severe growth hormone deficiency on a GHRP2 test.

    Peptide
    GHRP-2
    Outcome
    Not applicableSevere GHD by GHRP2 test
    Study

    n = 36

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    Severe GHD
    61%
    GHRP2 test

    Source sentences

    Summary
    Twenty-two (61%) had severe GHD
    1 context sentence
    Summary · context
    The GHRP2 test, a cosyntropin stimulation test, corticotropin-releasing hormone (CRH) tests and/or insulin tolerance tests (ITTs) were performed on 36 patients having hypothalamic-pituitary disorder.
  2. 02HumanObservational studyOther

    Among 36 patients with hypothalamic-pituitary disorder, 8% had moderate GH deficiency by the GHRP2 test.

    In plain wordsIn people with hypothalamic-pituitary disorder, 8% had moderate growth hormone deficiency on a GHRP2 test.

    Peptide
    GHRP-2
    Outcome
    Not applicableModerate GHD by GHRP2 test
    Study

    n = 36

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    Moderate GHD
    8%
    GHRP2 test

    Source sentences

    Summary
    Twenty-two (61%) had severe GHD, and 3 (8%) had moderate GHD by GHRP2.
    1 context sentence
    Summary · context
    The GHRP2 test, a cosyntropin stimulation test, corticotropin-releasing hormone (CRH) tests and/or insulin tolerance tests (ITTs) were performed on 36 patients having hypothalamic-pituitary disorder.
  3. 03HumanObservational studyOther

    In patients with hypothalamic-pituitary disorder, an ACTH response of 1.55-fold in the GHRP2 test screened for pituitary adrenal insufficiency with 83% sensitivity and 88% specificity.

    In plain wordsIn people with hypothalamic-pituitary disorder, the ACTH rise in a GHRP2 test helped screen for adrenal insufficiency.

    Peptide
    GHRP-2
    Outcome
    Not applicableACTH response in the GHRP2 test for screening pituitary adrenal insufficiency
    Study

    n = 36

    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    ACTH response cut-off
    1.55 fold
    GHRP2 test
    Sensitivity
    83%
    ACTH response cut-off
    Specificity
    88%
    ACTH response cut-off

    Source sentences

    Summary
    ROC curve analysis demonstrated that the ACTH response in the GHRP2 test was useful for screening pituitary-AI, with a cut-off value of 1.55-fold (83% sensitivity and 88% specificity).
    1 context sentence
    Summary · context
    The GHRP2 test, a cosyntropin stimulation test, corticotropin-releasing hormone (CRH) tests and/or insulin tolerance tests (ITTs) were performed on 36 patients having hypothalamic-pituitary disorder.
  4. 04HumanObservational studyOther

    In patients with hypothalamic-pituitary disorder, combining the ACTH response and the peak cortisol level in the GHRP2 test showed 100% specificity and 0.94 accuracy for pituitary adrenal insufficiency.

    In plain wordsIn people with hypothalamic-pituitary disorder, combining ACTH and cortisol rises in a GHRP2 test gave high accuracy for adrenal insufficiency.

    Peptide
    GHRP-2
    Outcome
    Not applicableCombined ACTH response and peak cortisol in the GHRP2 test for pituitary adrenal insufficiency
    Study

    n = 36

    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    ACTH response cut-off
    1.55 fold
    combined cut-offs
    Peak cortisol cut-off
    10 µg/dl
    combined cut-offs
    Specificity
    100%
    combined cut-offs
    Accuracy
    0.94
    combined cut-offs

    Source sentences

    Summary
    Notably, the combination of ACTH response and the peak cortisol level in the GHRP2 test using each cut-off value (1.55-fold and 10 µg/dl, respectively) showed high specificity (100%) with high accuracy (0.94) for diagnosis of pituitary-AI.
    1 context sentence
    Summary · context
    The GHRP2 test, a cosyntropin stimulation test, corticotropin-releasing hormone (CRH) tests and/or insulin tolerance tests (ITTs) were performed on 36 patients having hypothalamic-pituitary disorder.

Studies that did not test the peptide alone3

In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-2.

  1. 05HumanNot a test of GHRP-2 aloneObservational studyOther

    In patients with hypothalamic-pituitary disorder, baseline ACTH and cortisol did not differ between non-GHD, moderate GHD and severe GHD participants.

    In plain wordsIn people with hypothalamic-pituitary disorder, baseline ACTH and cortisol were similar across growth hormone deficiency groups.

    Peptide
    GHRP-2
    Outcome
    No significant changeBaseline ACTH and cortisol by GHD category
    Study

    n = 36

    Outcome group
    Stress hormones · Endocrine and hormones

    Source sentences

    Summary
    There was no difference in baseline ACTH and cortisol between non-GHD, moderate GHD and severe GHD participants.
    1 context sentence
    Summary · context
    The GHRP2 test, a cosyntropin stimulation test, corticotropin-releasing hormone (CRH) tests and/or insulin tolerance tests (ITTs) were performed on 36 patients having hypothalamic-pituitary disorder.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  2. 06HumanNot a test of GHRP-2 aloneObservational studyOther

    In patients with hypothalamic-pituitary disorder, 17 (47%) had secondary adrenal insufficiency by cosyntropin, CRH and insulin tolerance tests.

    In plain wordsIn people with hypothalamic-pituitary disorder, 47% had secondary adrenal insufficiency on other hormone tests.

    Peptide
    GHRP-2
    Outcome
    Not applicablePrevalence of secondary adrenal insufficiency
    Study

    n = 36

    Outcome group
    Stress hormones · Endocrine and hormones

    Measurements

    Secondary adrenal insufficiency
    47%
    cosyntropin, CRH, ITT

    Source sentences

    Summary
    However, a cosyntropin stimulation test and subsequent CRH tests and/or ITTs revealed that 17 (47%) had secondary AI and 16/17 (94%) cases of secondary AI were concomitant with severe GHD.
    1 context sentence
    Summary · context
    The GHRP2 test, a cosyntropin stimulation test, corticotropin-releasing hormone (CRH) tests and/or insulin tolerance tests (ITTs) were performed on 36 patients having hypothalamic-pituitary disorder.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  3. 07HumanNot a test of GHRP-2 aloneObservational studyOther

    In patients with hypothalamic-pituitary disorder, 16 of 17 (94%) cases of secondary adrenal insufficiency also had severe GH deficiency on the GHRP2 test.

    In plain wordsIn people with hypothalamic-pituitary disorder, almost all with secondary adrenal insufficiency also had severe growth hormone deficiency.

    Peptide
    GHRP-2
    Outcome
    Not applicableShare of secondary AI cases with severe GHD
    Study

    n = 36

    Outcome group
    Stress hormones · Endocrine and hormones

    Measurements

    Secondary AI with severe GHD
    94%
    16/17 cases

    Source sentences

    Summary
    However, a cosyntropin stimulation test and subsequent CRH tests and/or ITTs revealed that 17 (47%) had secondary AI and 16/17 (94%) cases of secondary AI were concomitant with severe GHD.
    1 context sentence
    Summary · context
    The GHRP2 test, a cosyntropin stimulation test, corticotropin-releasing hormone (CRH) tests and/or insulin tolerance tests (ITTs) were performed on 36 patients having hypothalamic-pituitary disorder.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    27 Oct 2026, 16:37 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    13 Oct 2026, 21:44 UTC

    Study results updated

  3. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.